Abstract:Background-Severe cardiac hypertrophy can lead to cardiac remodeling and even heart failure in the end, which is a leading cause of cardiovascular disease-related mortality worldwide. A disintegrin and metalloprotease-22 (ADAM22), a member of the transmembrane and secreted metalloendopeptidase family, participates in many biological processes, including those in the cardiovascular system. However, there is no explicit information on whether ADAM22 can regulate the process of cardiac hypertrophy; the effects that ADAM22 exerts in cardiac hypertrophy remain elusive. Methods and Results-We observed significantly increased ADAM22 expression in failing hearts from patients with dilated cardiomyopathy and hypertrophic cardiomyopathy; the same trend was observed in mice induced by transaortic constriction and in neonatal rat cardiomyocytes treated by angiotensin II. Therefore, we constructed both cardiac-specific ADAM22 overexpression and knockout mice. At 4weeks after transaortic constriction, cardiac-specific ADAM22 knockout, by the CRISPR/Cas9 (clustered regularly interspaced palindromic repeat (CRISPR)-Cas9) system, deteriorated the severity of cardiac hypertrophy in mice, whereas cardiac-specific ADAM22 overexpression mitigated the degrees of cardiac hypertrophy in mice. Similarly, altered ADAM22 expression modulated the angiotensin II-mediated cardiomyocyte hypertrophy in neonatal rat cardiomyocytes. After screening several signaling pathways, we found ADAM22 played a role in inhibition of protein kinase B (AKT) activation. Under the cardiac-specific ADAM22 knockout background, AKT activation was enhanced in transaortic constriction-induced mice and angiotensin II-stimulated neonatal rat cardiomyocytes, with a severe degree of cardiac hypertrophy. Treatment of a specific AKT inhibitor attenuated the transaortic constriction-enhanced AKT activation and cardiac hypertrophy in mice. Conclusions-The findings demonstrated that ADAM22 negatively regulates the AKT activation and the process of cardiac hypertrophy and may provide new insights into the pathobiological features of cardiac hypertrophy.

TANK Promotes Pressure Overload Induced Cardiac Hypertrophy via Activating AKT Signaling Pathway

TANK Promotes Pressure Overload Induced Cardiac Hypertrophy <i>via</i> Activating AKT Signaling Pathway

Abstract 026: Role of Tank in the Regulation of Pathological Cardiac Hypertrophy

TANK-binding Kinase 1 Alleviates Myocardial Ischemia/reperfusion Injury Through Regulating Apoptotic Pathway.

TAK1 is Activated in the Myocardium after Pressure Overload and is Sufficient to Provoke Heart Failure in Transgenic Mice.

Thymoquinone Ameliorates Pressure Overload‐induced Cardiac Hypertrophy by Activating the AMPK Signalling Pathway

Abstract P234: CTMP Negatively Regulates Pathological Cardiac Hypertrophy via Akt-dependent Manner

Tumor Necrosis Factor Receptor-Associated Factor 3 is A Positive Regulator of Pathological Cardiac Hypertrophy

Signal Transducer and Transcriptional Activation 1 Protects Against Pressure Overload‐induced Cardiac Hypertrophy

TRAF Family Member 4 Promotes Cardiac Hypertrophy Through the Activation of the AKT Pathway

Pak1 As A Novel Therapeutic Target for Antihypertrophic Treatment in the Heart

Long-Term Activation of Adenosine Monophosphate-Activated Protein Kinase Attenuates Pressure-Overload-Induced Cardiac Hypertrophy

NF-κB Activation is Required for the Development of Cardiac Hypertrophy in Vivo

Mechanism Of Enhanced Cardiac Function In Mice With Hypertrophy Induced By Overexpressed Akt

GW28-e0561 Inhibition of TRPA1 Ameliorates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis in Mice

Activation of the Cardiac Proteasome Promotes Angiotension II-induced Hypertrophy by Down-Regulation of ATRAP.

The Akt Pathway Mediates the Protective Effects of Myeloid Differentiation Protein 1 in Pathological Cardiac Remodelling

Augmented Cardiac Hypertrophy in Response to Pressure Overload in Mice Lacking Eltd1

Tnni3k, A Cardiac-Specific Kinase, Promotes Physiological Cardiac Hypertrophy In Transgenic Mice

The Ubiquitin E3 Ligase TRAF6 Exacerbates Pathological Cardiac Hypertrophy Via TAK1-dependent Signalling

A Disintegrin and Metalloprotease-22 Attenuates Hypertrophic Remodeling in Mice Through Inhibition of the Protein Kinase B Signaling Pathway.